12:00 AM
 | 
Sep 19, 2011
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 9/16 cls
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) Leerink Joshua Schimmer Upgrade Market outperform (from market perform) 17% $7.48
Schimmer also raised his target to the "mid-teens" from $11 ahead of Phase I biomarker data for ALN-TTR01 to treat transthyretin (TTR)-mediated amyloidosis, which he expects in November. He said the disease is clearly linked to an activating TTR mutation, making him "comfortable accepting biomarker data as early proof of concept" for the compound. ALN-TTR01 is a stable nucleic acid lipid particle (SNALP)-formulated RNAi targeting the TTR gene.
Dendreon Corp. (NASDAQ:DNDN) Roth Capital Partners Joseph Pantginis Downgrade Neutral (from buy) 2% $11.65
ThinkEquity Marko Kozul Price target Buy
Pantginis also lowered his target to $13 from $30, saying the demand curve for prostate cancer vaccine Provenge sipuleucel-T is "too cloudy." He will revisit his rating when Dendreon shows its ability to have Provenge "hit a meaningful stride." The product, which is...

Read the full 1092 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >